Based on a RAD001-resistant prostate cancer cell line, we recently reported that drug non-responsiveness is characterised by an increased level of cdk1 and cyclin B, which counteracts growth-blocking effects of this drug (Tsaur et al, 2011). Here, CDK1 is linked to prostate carcinoma.